Mark David Wilkie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark David Wilkie has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
Jeffrey Lancaster
Liverpool Head and Neck Centre, Department of Otolaryngology/Head and Neck Surgery Aintree University Hospital Liverpool UK
6 shared publicationsTerence M. Jones
Liverpool Head and Neck Centre, University Hospital Aintree, Lower Lane, Liverpool L9 7AL, United Kingdom
5 shared publicationsBenjamin Hall
3 shared publicationsKathryn A. Lightbody
Department of Otorhinolaryngology – Head and Neck Surgery University Hospital Aintree Liverpool United Kingdom
3 shared publicationsNicholas J. Roland
Liverpool Head and Neck Centre, University Hospital Aintree, Lower Lane, Liverpool L9 7AL, United Kingdom
3 shared publications- Nikolina Vlatković
MCP Hahnemann University Cancer Center, Philadelphia, PA 19102, USA
3 shared publications
Latest Publications
- Open Access
- 10 June 2026
- Published by Wiley in Clinical Otolaryngology
- Vol. 51 (5) , 752-760
Enhanced Recovery After Surgery Protocol in Transoral Robotic Surgery: A Case–Control Study
Introduction: ‘Enhanced Recovery After Surgery’ (ERAS) protocols have been developed for multiple surgical procedures with favourable outcome measures including Length of Stay (LoS). Trans‐Oral Robotic Surgery (TORS) has similarly facilitated earlier patient discharges, particularly in comparison to open head and neck surgical techniques. There is a dearth of literature on the effect of ERAS protocols in TORS. We sought to comprehensively examine the effect of a TORS ERAS protocol across several key metrics, with a focus on LoS. Methods: We conducted a retrospective cohort study following implementation of a TORS ERAS protocol. This protocol was developed at our institution and implemented in 2021; it included key features such as pharyngocutaneous risk stratification and thorough perioperative assessments. Patients managed prior to (p‐ERAS) and post implementation (w‐ERAS) were separated into two groups, with key outcomes, including LoS, estimated cost per patient, return to swallow, and complication rate, compared. Results: A total of 40 TORS cases were included. Patients managed w‐ERAS had a mean adherence rate to protocol of 90%. The w‐ERAS group showed a statistically significant reduction in median length of stay by 3.5 days ( p = 0.03) when compared to the p‐ERAS group. There was also a trend towards decreased median cost per patient as well as decreased median time to oral intake. Conclusion: Our study demonstrates an easily implementable protocol for the perioperative management of TORS oncological surgery. The use of this ERAS protocol demonstrated a significant reduction in patient length of stay in a small sample size.
- 10 June 2026
- Published by Wiley in Clinical Otolaryngology
- Vol. 51 (5) , 752-760
Open AccessEnhanced Recovery After Surgery Protocol in Transoral Robotic Surgery: A Case–Control Study
Introduction: ‘Enhanced Recovery After Surgery’ (ERAS) protocols have been developed for multiple surgical procedures with favourable outcome measures including Length of Stay (LoS). Trans‐Oral Robotic Surgery (TORS) has similarly facilitated earlier patient discharges, particularly in comparison to open head and neck surgical techniques. There is a dearth of literature on the effect of ERAS protocols in TORS. We sought to comprehensively examine the effect of a TORS ERAS protocol across several key metrics, with a focus on LoS. Methods: We conducted a retrospective cohort study following implementation of a TORS ERAS protocol. This protocol was developed at our institution and implemented in 2021; it included key features such as pharyngocutaneous risk stratification and thorough perioperative assessments. Patients managed prior to (p‐ERAS) and post implementation (w‐ERAS) were separated into two groups, with key outcomes, including LoS, estimated cost per patient, return to swallow, and complication rate, compared. Results: A total of 40 TORS cases were included. Patients managed w‐ERAS had a mean adherence rate to protocol of 90%. The w‐ERAS group showed a statistically significant reduction in median length of stay by 3.5 days ( p = 0.03) when compared to the p‐ERAS group. There was also a trend towards decreased median cost per patient as well as decreased median time to oral intake. Conclusion: Our study demonstrates an easily implementable protocol for the perioperative management of TORS oncological surgery. The use of this ERAS protocol demonstrated a significant reduction in patient length of stay in a small sample size.
- 12 January 2025
- Published by Wiley in Clinical Otolaryngology
- Vol. 50 (3) , 399-414
Head and Neck Squamous Cell Carcinoma of Unknown Primary—Who Can Be Offered Surgery as the Sole Treatment Modality? A Systematic Review
Objective: Evaluate the role of surgery as the sole treatment modality for patients with cervical head and neck squamous cell carcinoma of unknown primary (HNSCCUP).Design: Systematic review of observational cohort studies with qualitative synthesis.Setting: PubMed, Ovid EMBASE, and Cochrane Controlled register of Trials (CENTRAL) were screened from January 2000 up to October 2021.Participants: Patients with HNSCCUP after completing diagnostic workup subsequently treated with single‐modality surgery.Main Outcome Measures: The primary outcome was 3‐year overall survival (OS). Secondary outcomes included disease‐free survival (DFS), primary emergence, regional recurrence, and distant metastasis.Results: Fourteen eligible studies were identified, including 1780 patients, of whom 294 received surgery as their sole treatment (seven studies) with 3‐year OS ranging from 43.9% to 100%. 3‐year DFS was reported in four studies (n = 62) ranging from 42.8% to 67.0%. 5‐year OS and DFS were available in three studies (n = 31), ranging from 36.6% to 75.0%, and 43.6% to 67.0%, respectively. The rate of primary emergence ranged from 11.1% to 33.3% (seven studies, n = 157), regional relapse from 0.0% to 50.0% (five studies, n = 60) and distant metastasis from 0.0% to 3.3% (three studies, n = 45). Patients undergoing surgery as a sole treatment had predominantly p16/HPV positive N1 (TNM7) disease without ECS.Conclusion: Outcomes for HNSCCUP patients undergoing surgery alone range widely in the literature but may be reasonable in a subset of patients with early‐stage p16/HPV positive disease. Data is lacking for p16/HPV negative disease where the potential primary site is more varied and primary emergence appears more common.
- 12 January 2025
- Published by Wiley in Clinical Otolaryngology
- Vol. 50 (3) , 399-414
Head and Neck Squamous Cell Carcinoma of Unknown Primary—Who Can Be Offered Surgery as the Sole Treatment Modality? A Systematic Review
Objective: Evaluate the role of surgery as the sole treatment modality for patients with cervical head and neck squamous cell carcinoma of unknown primary (HNSCCUP).Design: Systematic review of observational cohort studies with qualitative synthesis.Setting: PubMed, Ovid EMBASE, and Cochrane Controlled register of Trials (CENTRAL) were screened from January 2000 up to October 2021.Participants: Patients with HNSCCUP after completing diagnostic workup subsequently treated with single‐modality surgery.Main Outcome Measures: The primary outcome was 3‐year overall survival (OS). Secondary outcomes included disease‐free survival (DFS), primary emergence, regional recurrence, and distant metastasis.Results: Fourteen eligible studies were identified, including 1780 patients, of whom 294 received surgery as their sole treatment (seven studies) with 3‐year OS ranging from 43.9% to 100%. 3‐year DFS was reported in four studies (n = 62) ranging from 42.8% to 67.0%. 5‐year OS and DFS were available in three studies (n = 31), ranging from 36.6% to 75.0%, and 43.6% to 67.0%, respectively. The rate of primary emergence ranged from 11.1% to 33.3% (seven studies, n = 157), regional relapse from 0.0% to 50.0% (five studies, n = 60) and distant metastasis from 0.0% to 3.3% (three studies, n = 45). Patients undergoing surgery as a sole treatment had predominantly p16/HPV positive N1 (TNM7) disease without ECS.Conclusion: Outcomes for HNSCCUP patients undergoing surgery alone range widely in the literature but may be reasonable in a subset of patients with early‐stage p16/HPV positive disease. Data is lacking for p16/HPV negative disease where the potential primary site is more varied and primary emergence appears more common.
- Open Access
- 29 May 2023
- Published by Wiley
Head and neck squamous cell carcinoma of unknown primary - Who can be offered surgery as the sole treatment modality? A systematic review
Objective Evaluate the role of neck dissection (ND) as the sole treatment modality for patients with cervical head and neck squamous cell carcinoma of unknown primary (HNSCCUP). Design Systematic review of observational cohort studies with qualitative synthesis. Setting PubMed, Ovid EMBASE, and Cochrane Controlled register of Trials (CENTRAL) were screened from January 2000 up to October 2021. Participants HNSCCUP patients undergoing ND. Main Outcome Measures The primary outcome was 3-year overall survival (OS). Secondary outcomes included disease-free survival (DFS), primary emergence, regional recurrence, and distant metastasis. Results Fourteen eligible studies were identified, including 1,780 patients, of whom 294 received ND as their sole treatment (seven studies) with 3-year OS ranging from 43.9% to 100%. 3-year DFS was reported in four studies (n=62) ranging from 42.8% to 67.0%. 5-year OS and DFS were available in three studies (n=31), ranging from 36.6% to 75.0%, and 43.6% to 67.0%, respectively. The rate of primary emergence ranged from 11.1% to 33.3% (seven studies, n=157), regional relapse from 0.0% to 50.0% (five studies, n=60), and distant metastasis from 0.0% to 3.3% (three studies, n=45). Patients undergoing ND as a sole treatment had predominantly p16 positive N1 (TNM7) disease without ECS. Conclusion Outcomes for HNSCCUP patients undergoing ND alone range widely in the literature but appear reasonable in a subset of patients with early stage p16 positive disease. Data is lacking for p16 negative disease where the potential primary site is more varied and primary emergence appears more common.
- 29 May 2023
- Published by Wiley
Open AccessHead and neck squamous cell carcinoma of unknown primary - Who can be offered surgery as the sole treatment modality? A systematic review
Objective Evaluate the role of neck dissection (ND) as the sole treatment modality for patients with cervical head and neck squamous cell carcinoma of unknown primary (HNSCCUP). Design Systematic review of observational cohort studies with qualitative synthesis. Setting PubMed, Ovid EMBASE, and Cochrane Controlled register of Trials (CENTRAL) were screened from January 2000 up to October 2021. Participants HNSCCUP patients undergoing ND. Main Outcome Measures The primary outcome was 3-year overall survival (OS). Secondary outcomes included disease-free survival (DFS), primary emergence, regional recurrence, and distant metastasis. Results Fourteen eligible studies were identified, including 1,780 patients, of whom 294 received ND as their sole treatment (seven studies) with 3-year OS ranging from 43.9% to 100%. 3-year DFS was reported in four studies (n=62) ranging from 42.8% to 67.0%. 5-year OS and DFS were available in three studies (n=31), ranging from 36.6% to 75.0%, and 43.6% to 67.0%, respectively. The rate of primary emergence ranged from 11.1% to 33.3% (seven studies, n=157), regional relapse from 0.0% to 50.0% (five studies, n=60), and distant metastasis from 0.0% to 3.3% (three studies, n=45). Patients undergoing ND as a sole treatment had predominantly p16 positive N1 (TNM7) disease without ECS. Conclusion Outcomes for HNSCCUP patients undergoing ND alone range widely in the literature but appear reasonable in a subset of patients with early stage p16 positive disease. Data is lacking for p16 negative disease where the potential primary site is more varied and primary emergence appears more common.
- 9 May 2023
- Published by Wiley in Clinical Otolaryngology
- Vol. 48 (5) , 773-778
Predictors of non‐functional larynx following (chemo)radiotherapy for locally advanced laryngeal cancer
- 9 May 2023
- Published by Wiley in Clinical Otolaryngology
- Vol. 48 (5) , 773-778
Predictors of non‐functional larynx following (chemo)radiotherapy for locally advanced laryngeal cancer
- Open Access
- 11 August 2022
- Published by Wiley
Predictors of non-functional larynx following (chemo)radiotherapy for locally advanced laryngeal cancer
• Non-functional larynx (NFL) was found to affect 30.9 % of patients with locally advanced laryngeal cancer who underwent curative non-surgical laryngeal preservation treatment for stage III/IV disease • The key measures of NFL were long-term gastrostomy and tracheostomy dependence, functional laryngectomy and chronic aspiration. • Multivariate analyses identified current smoking to be associated with 6.8-fold increase in NFL • Patients with pre-treatment hemi-laryngeal fixation were 3.4 times more likely to experience locoregional recurrence.
- 11 August 2022
- Published by Wiley
Open AccessPredictors of non-functional larynx following (chemo)radiotherapy for locally advanced laryngeal cancer
• Non-functional larynx (NFL) was found to affect 30.9 % of patients with locally advanced laryngeal cancer who underwent curative non-surgical laryngeal preservation treatment for stage III/IV disease • The key measures of NFL were long-term gastrostomy and tracheostomy dependence, functional laryngectomy and chronic aspiration. • Multivariate analyses identified current smoking to be associated with 6.8-fold increase in NFL • Patients with pre-treatment hemi-laryngeal fixation were 3.4 times more likely to experience locoregional recurrence.
- Open Access
Metabolic Plasticity and Combinatorial Radiosensitisation Strategies in Human Papillomavirus-Positive Squamous Cell Carcinoma of the Head and Neck Cell Lines
Background: A major objective in the management of human papillomavirus (HPV)-positive squamous cell carcinoma of the head and neck (SCCHN) is to reduce long-term functional ramifications while maintaining oncological outcomes. This study examined the metabolic profile of HPV-positive SCCHN and the potential role of anti-metabolic therapeutics to achieve radiosensitisation as a potential means to de-escalate radiation therapy. Methods: Three established HPV-positive SCCHN cell lines were studied (UM-SCC-104, UPCI:SCC154, and VU-SCC-147), together with a typical TP53 mutant HPV-negative SCCHN cell line (UM-SCC-81B) for comparison. Metabolic profiling was performed using extracellular flux analysis during specifically designed mitochondrial and glycolytic stress tests. Sensitivity to ionising radiation (IR) was evaluated using clonogenic assays following no treatment, or treatment with: 25 mM 2-deoxy-D-glucose (glycolytic inhibitor) alone; 20 mM metformin (electron transport chain inhibitor) alone; or 25 mM 2-deoxy-D-glucose and 20 mM metformin combined. Expression levels of p53 and reporters of p53 function (MDM2, p53, Phospho-p53 [Ser15], TIGAR and p21 [CDKN1A]) were examined by western blotting. Results: HPV-positive SCCHN cell lines exhibited a diverse metabolic phenotype, displaying robust mitochondrial and glycolytic reserve capacities. This metabolic profile, in turn, correlated with IR response following administration of anti-metabolic agents, in that both 2-deoxy-D-glucose and metformin were required to significantly potentiate the effects of IR in these cell lines. Conclusions: In contrast to our recently published data on HPV-negative SCCHN cells, which display relative glycolytic dependence, HPV-positive SCCHN cells can only be sensitised to IR using a complex anti-metabolic approach targeting both mitochondrial respiration and glycolysis, reflecting their metabolically diverse phenotype. Notionally, this may provide an attractive platform for treatment de-intensification in the clinical setting by facilitating IR dose reduction to minimise the impact of treatment on long-term function.
Open AccessMetabolic Plasticity and Combinatorial Radiosensitisation Strategies in Human Papillomavirus-Positive Squamous Cell Carcinoma of the Head and Neck Cell Lines
Background: A major objective in the management of human papillomavirus (HPV)-positive squamous cell carcinoma of the head and neck (SCCHN) is to reduce long-term functional ramifications while maintaining oncological outcomes. This study examined the metabolic profile of HPV-positive SCCHN and the potential role of anti-metabolic therapeutics to achieve radiosensitisation as a potential means to de-escalate radiation therapy. Methods: Three established HPV-positive SCCHN cell lines were studied (UM-SCC-104, UPCI:SCC154, and VU-SCC-147), together with a typical TP53 mutant HPV-negative SCCHN cell line (UM-SCC-81B) for comparison. Metabolic profiling was performed using extracellular flux analysis during specifically designed mitochondrial and glycolytic stress tests. Sensitivity to ionising radiation (IR) was evaluated using clonogenic assays following no treatment, or treatment with: 25 mM 2-deoxy-D-glucose (glycolytic inhibitor) alone; 20 mM metformin (electron transport chain inhibitor) alone; or 25 mM 2-deoxy-D-glucose and 20 mM metformin combined. Expression levels of p53 and reporters of p53 function (MDM2, p53, Phospho-p53 [Ser15], TIGAR and p21 [CDKN1A]) were examined by western blotting. Results: HPV-positive SCCHN cell lines exhibited a diverse metabolic phenotype, displaying robust mitochondrial and glycolytic reserve capacities. This metabolic profile, in turn, correlated with IR response following administration of anti-metabolic agents, in that both 2-deoxy-D-glucose and metformin were required to significantly potentiate the effects of IR in these cell lines. Conclusions: In contrast to our recently published data on HPV-negative SCCHN cells, which display relative glycolytic dependence, HPV-positive SCCHN cells can only be sensitised to IR using a complex anti-metabolic approach targeting both mitochondrial respiration and glycolysis, reflecting their metabolically diverse phenotype. Notionally, this may provide an attractive platform for treatment de-intensification in the clinical setting by facilitating IR dose reduction to minimise the impact of treatment on long-term function.
- 1 September 2021
- Published by Elsevier in Oral Oncology
- Vol. 120, 105432
Elective management of regional nodal basins in cutaneous squamous cell carcinoma of the head and neck: Controversies and contemporary perspectives
- 1 September 2021
- Published by Elsevier in Oral Oncology
- Vol. 120, 105432
Elective management of regional nodal basins in cutaneous squamous cell carcinoma of the head and neck: Controversies and contemporary perspectives
- 1 July 2021
- Published by Elsevier in Oral Oncology
- Vol. 118, 7
P-226 Emergency presentations of head and neck cancer: our experience in the wake of the COVID-19 pandemic
- 1 July 2021
- Published by Elsevier in Oral Oncology
- Vol. 118, 7
P-226 Emergency presentations of head and neck cancer: our experience in the wake of the COVID-19 pandemic
- Open Access
- 7 June 2021
- Published by Wiley in Clinical Otolaryngology
- Vol. 46 (6) , 1237-1241
Emergency presentations of head and neck cancer: Our experience in the wake of the COVID‐19 pandemic
Click on the article title to read more.
- 7 June 2021
- Published by Wiley in Clinical Otolaryngology
- Vol. 46 (6) , 1237-1241
Open AccessEmergency presentations of head and neck cancer: Our experience in the wake of the COVID‐19 pandemic
Click on the article title to read more.
- Open Access
- 15 April 2021
- Published by Wiley
EMERGENCY PRESENTATIONS OF HEAD AND NECK CANCER: OUR EXPERIENCE IN THE WAKE OF THE COVID-19 PANDEMIC
A document by Mark Wilkie, written on Authorea.
- 15 April 2021
- Published by Wiley
Open AccessEMERGENCY PRESENTATIONS OF HEAD AND NECK CANCER: OUR EXPERIENCE IN THE WAKE OF THE COVID-19 PANDEMIC
A document by Mark Wilkie, written on Authorea.